EP1056471A1 - TRAITEMENT DE LA DERMATITE ATOPIQUE A L'AIDE D'ANTAGONISTES D'IgE - Google Patents
TRAITEMENT DE LA DERMATITE ATOPIQUE A L'AIDE D'ANTAGONISTES D'IgEInfo
- Publication number
- EP1056471A1 EP1056471A1 EP99901309A EP99901309A EP1056471A1 EP 1056471 A1 EP1056471 A1 EP 1056471A1 EP 99901309 A EP99901309 A EP 99901309A EP 99901309 A EP99901309 A EP 99901309A EP 1056471 A1 EP1056471 A1 EP 1056471A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- ige
- pharmaceutical composition
- atopic dermatitis
- antibody
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Definitions
- the invention relates to use anti-IgE antagonists, including monoclonal
- Immunoglobulin E is one class of immunoglobulin (or "antibody")
- IgE is present in human serum in lower concentrations than the other
- immunoglobulins IgG, IgM, IgA, and IgD.
- IgE is thought to have a role in protection
- IgE is well known as the mediator of
- IgE In IgE-mediated allergic reactions, IgE, after it is secreted by B cells, binds
- IgE molecules and hence the underlying receptors, and triggers the release of
- pharmacologic mediators such as histamine, serotonin, leukotrienes and the slow-
- dermatitis is characterized by pruritis (itching), redness, and painful skin lesions.
- the skin can become lichenified.
- atopic dermatitis may have a link to IgE, but that IgE alone is not the causative
- a particular class of anti-IgE antibodies has been developed to treat allergic
- anti-IgE antibodies also bind to IgE which is attached to the membrane of IgE-
- B cells the "membrane form of IgE". By doing so, they may further aid
- ADCC ADCC
- complement mediated cytolysis the IgE-producing B cells
- Such antagonists would include small
- the invention includes a pharmaceutical composition for treating atopic
- dermatitis comprising IgE antagonists which do not induce release of the
- Such antagonists include monoclonal anti-IgE
- the anti-IgE antibodies present on basophils, mast cells, or Langerhans cells.
- the anti-IgE antibodies are present on basophils, mast cells, or Langerhans cells.
- anti-IgE antibodies preferably do not bind to IgE bound to the low affinity 4 Fc ⁇ RI I receptors. If the antibodies of the invention did bind to IgE bound to the low affinity 4 Fc ⁇ RI I receptors. If the antibodies of the invention did bind to IgE bound to the low affinity 4 Fc ⁇ RI I receptors. If the antibodies of the invention did bind to IgE bound to the low affinity 4 Fc ⁇ RI I receptors. If the antibodies of the invention did bind to IgE bound to the
- anti-IgE should prove to be a substantial
- IgE antagonist chosen is anti-IgE antibody, it can be modified in order
- the antibodies have a human lgG1 or lgG3 constant heavy
- composition which is not subject to digestive degradation, or through the alveoli of the 5 lung by an inhaler. It may also be possible to administer the composition topically
- the monoclonal anti-IgE antibodies used with are 100 in one specific embodiment, the monoclonal anti-IgE antibodies used with
- this invention are produced by continuous (immortalized), stable, antibody-
- the preferred antibody-producing cell lines are hybridoma and
- transfector ⁇ a cell lines can be any cell lines which contain and are
- Lymphoid cells which naturally produce assembled
- immunoglobulin are preferred.
- Hybridoma cells which produce the specific antibodies used with this
- IgE antibodies are produced by immunizing an animal with human IgE or IgE-
- Peptides can be synthesized or produced by recombinant DNA technology
- lymphoid cells ⁇ e.g., splenic
- lymphocytes are obtained from the immunized animal and fused with immortalizing
- hybrid cells ⁇ e.g., myeloma or heteromyeloma) to produce hybrid cells.
- the hybrid cells ⁇ e.g., myeloma or heteromyeloma
- anti-IgE is used for treating atopic dermatitis
- antibodies be either human or substantially human, to reduce or eliminate the
- HAMA human anti-mouse
- Human hybridomas which secrete human antibodies can be produced by the following
- mice are then cross-bred to generate the human antibody
- human antibody fragments for example, the single chain Fv region, by the phage
- PCR PCR reaction
- antibodies is to produce them in a rodent system, and convert them into chimeric
- Chimeric antibodies can be produced as described, for example, in
- One example of an anti-IgE antibody of the invention (designated TES-C21 )
- TESC-2 chimeric mouse-human form
- hybridoma cell lines producing TES-C21 are available from the
- Another humanized antibody suitable for treatment of atopic dermatitis is Another humanized antibody suitable for treatment of atopic dermatitis.
- E25 (rhuMAb-E25), produced by Genentech, Inc. This antibody is described in
- mice were immunized several times with polyclonal human IgE from sera
- hybridomas resulting from the fusion were then screened by enzyme-
- TES-C21 was further screened, by ELISA, to be specific for human IgE, and
- IgG IgM, IgA, IgD, human serum albumin, transferrin or insulin.
- TES-C21 bound equally well to various human IgE molecules. TES-C21 bound to
- murine cell line of SE44 or to a murine cell line secreting chimeric human IgG.
- TES-C21 also does not bind to IgE on high affinity Fc ⁇ RI receptors or on low affinity
- Fc ⁇ RI I receptors which are present on a wide variety of cell types. It also did not
- TESC-2 and TES-C21 bind equally well to IgE bound to microtiter plates.
- HRP horseradish peroxidase
- IgG goat antimouse IgG
- Immulon 2 plates were coated with gp120
- TES-C21 was detected using horseradish peroxidase-conjugated streptavidin.
- TESC-2 and TES-C21 also were shown to bind equally to IgE-producing
- TES-C21 was detected using FITC-goat (Fab') 2 antimouse IgG; binding of TESC-2
- IM-9 lymphoblastoid line
- TESC-2 labeled TESC-2 or a positive control anti-IgE MAb TES-19, followed by FITC-
- Binding of - IgE to cells was detected using biotinylated TES-19 and FITC-
- TESC-2 was further tested to determine whether it could block the binding
- the IgE antagonists, or antibodies, of the invention Prior to commercial availability, the IgE antagonists, or antibodies, of the invention
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7303398P | 1998-01-29 | 1998-01-29 | |
US1526998A | 1998-01-29 | 1998-01-29 | |
US15269 | 1998-01-29 | ||
US73033P | 1998-01-29 | ||
PCT/US1999/000135 WO1999038531A1 (fr) | 1998-01-29 | 1999-01-06 | TRAITEMENT DE LA DERMATITE ATOPIQUE A L'AIDE D'ANTAGONISTES D'IgE |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1056471A1 true EP1056471A1 (fr) | 2000-12-06 |
EP1056471A4 EP1056471A4 (fr) | 2001-05-30 |
Family
ID=26687160
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99901309A Withdrawn EP1056471A4 (fr) | 1998-01-29 | 1999-01-06 | TRAITEMENT DE LA DERMATITE ATOPIQUE A L'AIDE D'ANTAGONISTES D'IgE |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1056471A4 (fr) |
JP (1) | JP2002501905A (fr) |
CN (1) | CN1289253A (fr) |
AU (1) | AU2103699A (fr) |
WO (1) | WO1999038531A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2000481E (pt) * | 2003-02-01 | 2016-06-17 | Tanox Inc | Anticorpos anti-ige humana de alta afinidade |
AU2008215926B2 (en) * | 2007-02-15 | 2012-07-19 | Astrazeneca Ab | Binding members for IgE molecules |
GB201610198D0 (en) * | 2016-06-10 | 2016-07-27 | Ucb Biopharma Sprl | Anti-ige antibodies |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992017207A1 (fr) * | 1991-03-26 | 1992-10-15 | Tanox Biosystems, Inc. | ANTICORPS MONOCLONAUX QUI SE LIENT A L'IgE SECRETEE ET LIEE AUX MEMBRANES MAIS QUI NE SE LIENT PAS A L'IgE SE TROUVANT SUR LES LEUCOCYTES BASOPHILES |
EP0589840A1 (fr) * | 1992-09-24 | 1994-03-30 | Ciba-Geigy Ag | Anticorps monoclonaux transformés contre une isotype d'immunoglobuline |
EP0648499A1 (fr) * | 1993-10-19 | 1995-04-19 | Chisei Ra | Composition pour l'inhibition de la production d'IgE |
EP0657534A1 (fr) * | 1992-08-04 | 1995-06-14 | The Green Cross Corporation | Agent antiallergique |
WO1998004718A1 (fr) * | 1996-07-26 | 1998-02-05 | Novartis Ag | Polypeptides de fusion comprenant un domaine de liaison ige et un composant hsa, et leurs utilisations diagnostiques et therapeutiques |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5449760A (en) * | 1987-12-31 | 1995-09-12 | Tanox Biosystems, Inc. | Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils |
-
1999
- 1999-01-06 AU AU21036/99A patent/AU2103699A/en not_active Abandoned
- 1999-01-06 JP JP2000529263A patent/JP2002501905A/ja active Pending
- 1999-01-06 CN CN99802505A patent/CN1289253A/zh active Pending
- 1999-01-06 EP EP99901309A patent/EP1056471A4/fr not_active Withdrawn
- 1999-01-06 WO PCT/US1999/000135 patent/WO1999038531A1/fr not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992017207A1 (fr) * | 1991-03-26 | 1992-10-15 | Tanox Biosystems, Inc. | ANTICORPS MONOCLONAUX QUI SE LIENT A L'IgE SECRETEE ET LIEE AUX MEMBRANES MAIS QUI NE SE LIENT PAS A L'IgE SE TROUVANT SUR LES LEUCOCYTES BASOPHILES |
EP0657534A1 (fr) * | 1992-08-04 | 1995-06-14 | The Green Cross Corporation | Agent antiallergique |
EP0589840A1 (fr) * | 1992-09-24 | 1994-03-30 | Ciba-Geigy Ag | Anticorps monoclonaux transformés contre une isotype d'immunoglobuline |
EP0648499A1 (fr) * | 1993-10-19 | 1995-04-19 | Chisei Ra | Composition pour l'inhibition de la production d'IgE |
WO1998004718A1 (fr) * | 1996-07-26 | 1998-02-05 | Novartis Ag | Polypeptides de fusion comprenant un domaine de liaison ige et un composant hsa, et leurs utilisations diagnostiques et therapeutiques |
Non-Patent Citations (4)
Title |
---|
CORNE JONATHAN ET AL: "The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: Efficacy, safety, and pharmacokinetics." 1997 , JOURNAL OF CLINICAL INVESTIGATION, VOL. 99, NR. 5, PAGE(S) 879-887 XP002164091 ISSN: 0021-9738 * the whole document * * |
GRAHAM BROWN R. A. C. ET AL.: "Therapeutics in atopic dermatitis" 1997 , ADVANCES IN DERMATOLOGY, VOL. 13, PAGE(S) 3-31 XP000983988 * page 8 - page 9 * * |
HAAK-FRENDSCHO M. ET AL.: "Human IgE receptor alpha-chain IgG chimera blocks passive cutaneous anaphylaxis reaction in vivo" 1993 , JOURNAL OF IMMUNOLOGY, VOL. 151, NR.1, PAGE(S) 351-358 XP000942183 * page 354, right-hand column, paragraph 2 * * page 357, left-hand column * * |
See also references of WO9938531A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO1999038531A1 (fr) | 1999-08-05 |
CN1289253A (zh) | 2001-03-28 |
JP2002501905A (ja) | 2002-01-22 |
EP1056471A4 (fr) | 2001-05-30 |
AU2103699A (en) | 1999-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5543144A (en) | Treating hypersensitivities with anti-IGE monoclonal antibodies which bind to IGE-expressing B cells but not basophils | |
Brüggemann et al. | The immunogenicity of chimeric antibodies. | |
JP4153560B2 (ja) | アレルギー性喘息の治療法 | |
US5656273A (en) | Method of treatment of parasitic infection using IgE antagonists | |
RU2550270C2 (ru) | АНТИ-CemX АНТИТЕЛА, СПОСОБНЫЕ СВЯЗЫВАТЬСЯ С migE ЧЕЛОВЕКА НА В ЛИМФОЦИТАХ | |
Davis et al. | Can anti-IgE be used to treat allergy? | |
US20050136051A1 (en) | Methods for generating multimeric molecules | |
DE69126607T2 (de) | Extrazelluläre teilstücke humaner ige-immunoglobulin-ankerpeptide und dafür spezifische antikörper | |
EP0585224A1 (fr) | ANTICORPS MONOCLONAUX QUI SE LIENT A L'IgE SECRETEE ET LIEE AUX MEMBRANES MAIS QUI NE SE LIENT PAS A L'IgE SE TROUVANT SUR LES LEUCOCYTES BASOPHILES | |
US20110311520A1 (en) | Methods for treatment of allergic asthma | |
JP2002510211A (ja) | 改良抗IgE抗体及びポリペプチドの改良方法 | |
JP2007501847A (ja) | 自己/同種免疫状態の治療用抗FcRn抗体 | |
JP2002538170A (ja) | 喘息の治療における抗−TNFα抗体 | |
US20020076404A1 (en) | Treating atopic dermatitis with IgE antagonists | |
EP1056471A1 (fr) | TRAITEMENT DE LA DERMATITE ATOPIQUE A L'AIDE D'ANTAGONISTES D'IgE | |
JP5773882B2 (ja) | 抗FasLリガンド抗体を含有する天疱瘡用治療薬 | |
JP2001506122A (ja) | 免疫抑制作用を有するモノクローナル抗体断片 | |
US20020006402A1 (en) | Administering IgE antagonists during pregnancy to ameliorate allergic diseases in the offspring | |
Ball et al. | Isolation and characterization of human monoclonal antibodies to digoxin | |
WO2000072879A1 (fr) | TRAITEMENT DE MALADIES ALLERGIQUES PAR L'IMMUNOTHERAPIE ET LES ANTAGONISTES DE L'IgE | |
Hannestad et al. | Anti‐idiotypic immune responses against adjuvant‐free isologous IgM monoclonal antibodies and their augmentation by complex formation between IgM and albumin in bovine serum | |
CN107648609A (zh) | Il‑35对脓毒症中效应性t细胞自噬的抑制作用 | |
Salagean et al. | IgE and Anti-IgE Therapy in Allergic Asthma and Rhinitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20000828 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20010412 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20020829 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20040810 |